KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment: 2017-2025

Historic Asset Writedowns and Impairment for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Sep 2025 value amounting to $22.8 million.

  • Amneal Pharmaceuticals' Asset Writedowns and Impairment rose 3.08% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.5 million, marking a year-over-year increase of 24.34%. This contributed to the annual value of $96.6 million for FY2024, which is 29.29% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Asset Writedowns and Impairment is $22.8 million, which was down 3.67% from $23.7 million recorded in Q1 2025.
  • Amneal Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $32.9 million during Q4 2024, with a 5-year trough of $3.6 million in Q1 2022.
  • In the last 3 years, Amneal Pharmaceuticals' Asset Writedowns and Impairment had a median value of $22.5 million in 2024 and averaged $21.8 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first plummeted by 77.67% in 2022, then skyrocketed by 604.42% in 2023.
  • Amneal Pharmaceuticals' Asset Writedowns and Impairment (Quarterly) stood at $15.4 million in 2021, then surged by 44.52% to $22.2 million in 2022, then declined by 18.74% to $18.0 million in 2023, then soared by 82.54% to $32.9 million in 2024, then grew by 3.08% to $22.8 million in 2025.
  • Its last three reported values are $22.8 million in Q3 2025, $23.7 million for Q1 2025, and $32.9 million during Q4 2024.